New BEACON
Presented by Dr Martina Eriksen (Rigshospitalet, Copenhagen, Denmark)
In this video, Dr Martina Eriksen, medical oncologist at the Rigshospitalet in Copenhagen (Denmark) shares the results of an interim analysis of the New-BEACON study. This trial evaluates cetuximab given every second week together with daily encorafenib in the second line treatment of patients with BRAF-mutant metastatic colorectal cancer (mCRC). Interim data of this trial showed a 2-month progression free survival (PFS) rate of 89%, which is comparable to the results obtained in the BEACON trial evaluating a weekly administration of cetuximab. As such, these results suggest that cetuximab every second week may be suitable alternative to weekly cetuximab in this setting.
References:
Eriksen M, et al. ASCO GI 2025; Abstract 153
